BNR: מקדם מחיר להכנסות Burning Rock Biotech Ltd.

The Burning Rock Biotech (BNR) P/S chart on GURU.Markets helps assess the business valuation, where the current value is 1.60. This valuation accounts for regulatory complexities in China and margin pressure. Growth relies on the mass adoption of NGS tests and liquid biopsy. Stability is ensured by a strong staff of molecular biologists, despite competition for data scientists.

The multiple is calculated as the ratio of Burning Rock Biotech (BNR) current market capitalization to its annual sales volume. This coefficient compares market expectations with actual cash flows, revealing either an undervalued asset or stagnation in its development. For this molecular diagnostics developer, the metric reflects the scaling efficiency of centralized laboratories and the automation of DNA analysis. The company's P/S dynamics allow for an objective valuation of the business relative to its revenue growth rates.